Dr Tracie-Ann Madden

2023

• Beresford, M. et al., 2023. Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial. BJC Reports 1 (1) 13. (10.1038/s44276-023-00016-8)
• Butler, C. C. et al. 2023. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. The Lancet 401 (10373)(10.1016/S0140-6736(22)02597-1)
• Gbinigie, O. et al., 2023. Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease. BMJ Open 13 e069176. (10.1136/bmjopen-2022-069176)

2020

• Jones, R. et al., 2020. A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer patients not suitable to receive cisplatin. BJU International 126 (2), pp.292-299. (10.1111/bju.15096)
• Jones, R. H. et al. 2020. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology 21 (3), pp.345-347. (10.1016/S1470-2045(19)30817-4)

2018

• Hurt, C. N. et al. 2018. Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multi-centre, randomised, phase II trial (RT3VIN). BJOG: An International Journal of Obstetrics and Gynaecology 125 (9), pp.1171-1177. (10.1111/1471-0528.15124)

2016

• Jones, R. J. et al., 2016. TOUCAN: A randomised phase II trial of carboplatin and gemcitabine plus /- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin [Abstract]. American Journal of Clinical Oncology 34 (S25) 448.

2014

• Tristram, A. et al. 2014. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology 15 (12), pp.1361-1368. (10.1016/S1470-2045(14)70456-5)

2003

• Hutcheson, I. R. et al. 2003. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81 (1), pp.81-93. (10.1023/A:1025484908380)
• Knowlden, J. M. et al. 2003. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 (3), pp.1032-1044. (10.1210/en.2002-220620)
• Nicholson, R. I. et al. 2003. The biology of antihormone failure in breast cancer. Breast Cancer Research and Treatment 80 (S1), pp.29-34. (10.1023/A:1025467500433)

2002

• Gee, J. M. W. et al. 2002. ZD1839 ('Iressa') improves the antitumour activity of tamoxifen ('Nolvadex') and ICI 182, 780 ('Faslodex') in antihormone responsive breast cancer [Abstract]. European Journal of Cancer 38 (S7), pp.S59. (10.1016/S0959-8049(02)80835-8)

2001

• McClelland, R. A. et al. 2001. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142 (7), pp.2776-2788. (10.1210/en.142.7.2776)
• Nicholson, R. I. et al. 2001. ZD1839 (Iressa) improves the antitumor activity of tamoxifen (Nolvadex) in antihormone-responsive breast cancer cells [Abstract]. Clinical Cancer Research 7 (S), pp.3766S.

2000

• Madden, T. et al. 2000. Modulation of oestrogen action by receptor gene inhibition. European Journal of Cancer 36 (S4), pp.34-35. (10.1016/S0959-8049(00)00216-1)